ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lamivudine

Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.

Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 15, 200049 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only352 open or runningphase 4since Feb 15, 2000Nov 2, 1999Sep 14, 2032phase 3 · NCT07393659
Bristol-Myers Squibb70 open or runningphase 4since Jun 27, 2005Nov 2, 1999none ahead
Abbottits history only40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Dupont Merckits history only20 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Triangle Pharmaceuticalsits history only10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 3 study in HIV InfectionsFirst studyNCT00002371 · 80 enrolled · United States, Canada, Puerto Rico
  2. Mar 31, 2001Phase 3 study in HIV InfectionsNCT00013897 · United States, Austria, Belgium and more
  3. Jun 27, 2005Phase 4 study in HIV InfectionsNCT00116116 · 70 enrolled · United States
  4. Jun 28, 2005Phase 3 study in HIV InfectionsNCT00116298 · 900 enrolled · United States, Argentina, Belgium and more
  5. Aug 25, 2005Phase 3 study in HIV InfectionsNCT00135369 · 300 enrolled · United States, Puerto Rico
  6. Dec 11, 2006Phase 3 study in Hepatitis B, ChronicNCT00410202 · 629 enrolled · United States, Australia, Brazil and more
  7. Jun 13, 2012Phase 3 study in HIVNCT01620944 · 3 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 7 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01620944HIV3TerminatedJan 22, 20133
NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more3CompletedJan 2011629
NCT00135369HIV Infections · United States, Puerto Rico3CompletedJul 2005300
NCT00116298HIV Infections · United States, Argentina, Belgium and more3CompletedJan 2005900
NCT00116116HIV Infections · United States4CompletedJun 200570
NCT00013897HIV Infections · United States, Austria, Belgium and more3CompletedApr 2003
NCT00002371HIV Infections · United States, Canada, Puerto Rico3CompletedDec 199780

How it is read

Names in the registry

  • “Lamivudine”, 35 entries
  • “Lamivudine/Zidovudine”, 6 entries
  • “Lamivudine (3TC)”, 4 entries
  • “lamivudine”, 3 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.